SLC5A2 and inherited lipid metabolism disorder: The non‐SGLT2 inhibitor group had a higher proportion of patients with dyslipidaemia and higher mean total, HDL and LDL cholesterol levels, whereas triglyceride levels were higher in the SGLT2 inhibitor cohort, which also had higher glycated haemoglobin (HbA1c) levels.